COHERUS ONCOLOGY INC (CHRS) Stock Price, Forecast & Analysis
USA - NASDAQ:CHRS - US19249H1032 - Common Stock
CHRS Key Statistics, Chart & Performance
The current stock price of CHRS is 1.16 USD. In the past month the price decreased by -29.7%. In the past year, price increased by 6.42%.
CHRS Latest News, Press Relases and Analysis
CHRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About CHRS
Company Profile
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 177 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
Company Info
COHERUS ONCOLOGY INC
333 Twin Dolphin Dr, Suite 600, 201 Redwood Shores Parkway, Suite 200
Redwood City CALIFORNIA 94065 US
CEO: Dennis M. Lanfear
Employees: 228
Phone: 16506493530
COHERUS ONCOLOGY INC / CHRS FAQ
What does COHERUS ONCOLOGY INC do?
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 177 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
Can you provide the latest stock price for COHERUS ONCOLOGY INC?
The current stock price of CHRS is 1.16 USD. The price increased by 5.45% in the last trading session.
What is the dividend status of COHERUS ONCOLOGY INC?
CHRS does not pay a dividend.
What is the ChartMill rating of COHERUS ONCOLOGY INC stock?
CHRS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CHRS stock?
CHRS stock is listed on the Nasdaq exchange.
How many employees does COHERUS ONCOLOGY INC have?
COHERUS ONCOLOGY INC (CHRS) currently has 228 employees.
When does COHERUS ONCOLOGY INC (CHRS) report earnings?
COHERUS ONCOLOGY INC (CHRS) will report earnings on 2026-03-09, after the market close.
CHRS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CHRS. When comparing the yearly performance of all stocks, CHRS turns out to be only a medium performer in the overall market: it outperformed 52.17% of all stocks.
CHRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CHRS. Both the profitability and financial health of CHRS have multiple concerns.
CHRS Financial Highlights
Over the last trailing twelve months CHRS reported a non-GAAP Earnings per Share(EPS) of -1.3. The EPS decreased by -19.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 185.44% | ||
| ROA | 30% | ||
| ROE | 176.56% | ||
| Debt/Equity | 0.58 |
CHRS Forecast & Estimates
11 analysts have analysed CHRS and the average price target is 5.78 USD. This implies a price increase of 398.28% is expected in the next year compared to the current price of 1.16.
For the next year, analysts expect an EPS growth of -66.6% and a revenue growth -82.03% for CHRS